Can Trump Cut Prescription Prices?

Episode Summary

Executive Summary: The episode examines Trump’s executive order on prescription drug prices, arguing that U.S. drug costs are driven by a mix of international price differences, fragmented purchasing, patent protection, FDA rules, and misaligned incentives involving PBMs, doctors, and insurers. It weighs price controls against market-based reforms, concluding there are real trade-offs and no easy fix.

Main Topics: Trump’s executive order on drug prices (Priority: 5/5): The episode opens with Trump’s order targeting pharmaceutical overcharging, questioning whether it signals real policy or a vague threat without legislative power. Why U.S. drug prices are so high (Priority: 5/5): Explains the structural reasons U.S. prices exceed those abroad: fragmented negotiation, brand-name pricing, patents, R&D costs, and market exclusivity. International comparisons and importation (Priority: 4/5): Discusses Canada-style price controls, Sanders’s advocacy, Florida’s importation attempt, and the practical limits of importing drugs from abroad. FDA approval, safety, and innovation trade-offs (Priority: 4/5): Reviews the history of drug regulation and argues faster approval can help access but also raises safety and effectiveness trade-offs. PBMs, insurers, doctors, and incentive problems (Priority: 5/5): Argues that intermediaries like PBMs and some providers can benefit from higher list prices, helping explain why prices remain elevated. Patents, exclusivity, and evergreening (Priority: 4/5): Describes how patents and post-approval exclusivity extend market dominance far beyond the nominal 20 years, delaying cheaper competition. Possible reforms without strict price controls (Priority: 3/5): Outlines alternatives such as importation, shorter patent terms, and lower FDA approval costs as market-based ways to reduce prices.

Key Arguments: U.S. drug prices are high because the American system fragments purchasing power across many payers, unlike countries that negotiate centrally. Brand-name drugs are much more expensive in the U.S., but generic drugs are often cheaper than abroad, so the problem is concentrated in patented and exclusive products. Price controls can reduce prices but may also reduce availability, as seen in countries where some new drugs are not offered at all. PBMs and other intermediaries can have incentives that favor high list prices because their compensation is tied to discounts and spreads. The FDA has become faster over time, but quicker review does not eliminate the large total cost and time required to develop a drug. Drug companies argue high U.S. prices are partly needed to recover massive R&D costs across a small number of eventual approvals. Patents are supposed to create temporary monopolies to encourage innovation, but evergreening often extends that monopoly far beyond the nominal term. Direct-to-consumer sales, foreign importation, shorter patent protection, and cheaper approvals could reduce prices without formal price controls, but each has trade-offs.

Data Points: U.S. prescription drug prices vs. rest of world: Almost 3x higher - Research cited in the episode comparing prescription drug costs in America to other wealthy countries. Brand-name drug prices: 4.22x higher in the U.S. - The gap is largest for branded medicines. Generic drug volume share: 90% of prescription drug volumes - Unbranded generics account for the overwhelming majority of prescriptions. U.S. generic drug prices vs. Canada: 15% to 20% cheaper in the U.S. - Used to explain why Canadian importation would have limited impact on most prescriptions. Canadian access to new drugs: 45% - Share of 460 new drugs introduced worldwide from 2012 to 2021 that were available to Canadian patients. U.S. access to new drugs: 85% - Share of those same new drugs available to American patients if they could afford them. Florida importation plan: 14 drugs - Drugs Florida identified for import from Canada. Florida importation spending: $50 million - Amount Florida reportedly spent on a warehouse to store medicines. Import/distributor fees: Over $24 million - Florida paid an importer and distributor despite no drugs being imported. Monthly fee increase: $1.2 million per month - Ongoing cost increase cited in Florida’s lawsuit against the FDA. Share of healthcare spending in Europe: About 10% of GDP - Used to compare overall system costs with the U.S. Share of healthcare spending in the U.S.: About 18% of GDP - Illustrates the higher overall cost of American healthcare. Drug share of total healthcare costs: 10% to 12% - Drugs are not the biggest driver of total healthcare spending in either the U.S. or Europe. EpiPen price: $300 per dose - Used as a prominent example of U.S. drug pricing outrage. Orkambi U.S. annual cost: Around $270,000 per patient per year - Cystic fibrosis drug example showing high U.S. launch pricing. Orkambi NHS discount: About 50% - Even discounted, the drug remained too expensive for the UK system. FDA fees from pharma in 1993: $66 million - User Fee Act funding level when the FDA began charging companies for reviews. FDA fees from pharma in 2018: More than 12x 1993 level - Shows how user-fee funding expanded over time. FDA review time: Less than 1 year in 2017 - Drug review times declined substantially from the early 1980s. FDA review time in 1983: More than 3 years - Historical comparison for approval speed. Total time from clinical testing to approval: About 8 years - Shown as roughly constant over time despite faster review stages. R&D spending in 2021: $276 billion - Industry-wide R&D spending cited as a key justification for high prices. Approval rate for new molecules: About 12% - Only a small fraction of molecules make it through the approval process. FDA-approved new drugs last year: 50 - Used to estimate R&D cost per approved drug. Estimated R&D cost per new drug: $5.52 billion - Derived by dividing annual R&D spending by the number of approved drugs. Market dominance after approval: About 12 years - Estimated period during which a drug can earn returns before competition arrives. Patent term: 20 years - The statutory monopoly granted to inventors. Projected patent protection for top 10 drugs: 40.5 years - Cornell study on evergreening and extended protection. Medicaid rebate: 23.1% - Minimum statutory rebate mentioned for certain drugs under Medicaid. GLP-1 shortage declaration: 2022 - FDA shortage ruling that allowed compounded versions of the drug. GlP-1 availability change: Recently removed from shortage list - Triggered the phaseout of compounded versions. Planned 2025 drug price increases: Approximately 4.5% on at least 250 brands - Reuters report on expected manufacturer price changes. Daraprim price hike: From $13.50 to $750 per pill - Martin Shkreli case cited as an example of extreme price exploitation. Novartis gene therapy price: $2.1 million - Example of a one-time ultra-high-priced treatment for a rare inherited disease.

Pivotal Quotes: "there is a 4,000-year history of well-meaning governments. imposing price controls, but no successful examples" — Host/narrator: Used to argue that price controls often fail because market prices allocate scarce resources. "if Trump is serious about making real change rather than just issuing a press release, he will support the legislation" — Bernie Sanders: Sanders responds to Trump’s order by calling for statutory action on international reference pricing. "it's the identical pill that I buy in New York. And here I'm paying $88 in London. In New York, I'm paying $1,300. Now this is a great businessman, but he's not familiar with this crazy situation that we have." — Donald Trump: Anecdote used to illustrate perceived unfairness in U.S. drug pricing.

Implications: Drug prices are unlikely to fall from rhetoric alone; durable change would require legislative reform, better purchasing power, or broader market changes. But each option has trade-offs involving access, innovation, and supply.